Forest/Cypress Fibromyalgia Treatment Milnacipran Aims To Take On Pfizer’s Lyrica With More Robust Data
This article was originally published in The Pink Sheet Daily
Executive Summary
Cypress Chief Business Officer tells the DAILY that use of a more stringent composite endpoint could provide advantage for milnacipran over Lyrica and other potential treatments.